CelcuityCELC
CELC
About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Employees: 87
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
1.39% more ownership
Funds ownership: 81.83% [Q4 2024] → 83.22% (+1.39%) [Q1 2025]
9% less funds holding
Funds holding: 103 [Q4 2024] → 94 (-9) [Q1 2025]
22% less capital invested
Capital invested by funds: $402M [Q4 2024] → $312M (-$89.4M) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
63% less call options, than puts
Call options by funds: $192K | Put options by funds: $525K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
25%
downside
Avg. target
$42
10%
upside
High target
$60
56%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Andrew Berens | 56%upside $60 | Outperform Maintained | 28 Jul 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 30%upside $50 | Buy Maintained | 28 Jul 2025 |
Needham Gil Blum | 25%downside $29 | Buy Reiterated | 28 Jul 2025 |
Stifel Stephen Willey | 22%downside $30 | Buy Reinstated | 1 Jul 2025 |
Financial journalist opinion
Based on 10 articles about CELC published over the past 30 days
Positive
Forbes
21 hours ago
Celcuity: What's Happening With CELC Stock?
Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 before stabilizing around $37. This dramatic price movement was triggered by positive topline results from the PIK3CA wild-type cohort of the company's Phase 3 VIKTORIA-1 clinical trial for gedatolisib, a targeted therapy for HR+/HER2- breast cancer.
Neutral
GlobeNewsWire
1 day ago
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $150,000,000 aggregate principal amount of its convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $75,000,000 of shares of its common stock (the “Common Stock” and, such offering, the “Common Stock Offering”).
Positive
Invezz
1 day ago
Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success
Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results from a Phase 3 clinical trial of its investigational breast cancer treatment. The stock was set for its best day on record if it held the gains.
Positive
Schaeffers Research
1 day ago
Biotech Stock Blasting Off After Late-Stage Trial Results
Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes will have Food & Drug Administration (FDA) approval by the end of the year.
Positive
Reuters
1 day ago
Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study
Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket trading.
Neutral
GlobeNewsWire
1 day ago
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
Hazard Ratios and Improvements in Median PFS are Unprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”)
Neutral
GlobeNewsWire
4 days ago
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Neutral
GlobeNewsWire
5 days ago
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has been dosed in VIKTORIA-2, its Phase 3 clinical trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer (“ABC”) who are endocrine therapy resistant. Gedatolisib is an investigational, multi-target PI3K/AKT/mTOR (“PAM”) inhibitor that potently targets all four class I PI3K isoforms, mTORC1, and mTORC2 to induce comprehensive blockade of the PAM pathway.
Neutral
GlobeNewsWire
2 weeks ago
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity's patent exclusivity in the U.S. into 2042.
Neutral
GlobeNewsWire
4 weeks ago
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66%
Charts implemented using Lightweight Charts™